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A B S T R A C T
The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to healing and relief
from gastroesophageal reflux disease-related symptoms. I this multicentre, randomized, single-blind study 180 patients
(ITT population) diagnosed with endoscopically proven GERD grade A,B,C received esomeprazole (40 mg once daily
(o.d.), n=90) or pantoprazole (40 mg o.d., n=90). Healing and relief from GERD-related symptoms were assessed at first
and final visit (after 4 or 8 weeks of treatment). Esomeprazole 40 mg provided significantly greater healing than pan-
toprazole 40 mg after 4 weeks of treatment in patients with EE (77.8% vs. 72.2%). Esomeprazole-treated patients were
healed after up to 8 weeks of treatment similar those treated with pantoprazole (92.2% vs. 91.1%). The proportion of
heartburn-free days was similar in patients treated with esomeprazole and to those treated with pantoprazole.
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Introduction
Gastroesophageal reflux disease (GERD) is an ex-
tremely common clinical problem accounting for a large
proportion of physician visits regarding gastrointestinal
problems.
GERD is associated with severe and frequently life-
-long symptoms that lead to a marked reduction in nor-
mal function and well-being1. Up to 50% of patients with
chronic GERD develop erosive oesophagitis (EE)2. GERD
and/or EE are associated with complications such as pep-
tic stricture, bleeding and Barrett's oesophagus; the lat-
ter is a risk factor for oesophageal adenocarcinoma3. Pa-
tients with GERD have a diverse range of symptoms, the
most common of which is heartburn4. The goals of man-
agement in patients with GERD are healing of EE, reso-
lution of symptoms and prevention of complications5.
The most effective and established drugs to inhibit gas-
tric acid secretion are proton pump inhibitors (PPIs),
which are nowadays recommended as the treatment of
choice for GERD6.
The aim of this study was to compare esomeprazole 40
mg with pantoprazole 40 mg for healing and symptom re-
lief in patient with EE. The results presented here relate
to the acute treatment phase of a management study.
Methods
Patients with EE were enrolled into this randomized,
single blind, multi-centre study. The study was undertaken
in accordance with the Declaration of Helsinki and with
the prior approval of local ethics committees. Informed
consent was obtained from all patients prior to study entry.
The study was conducted at 3 centres in Croatia.
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Inclusion criteria included: history of GERD symp-
toms for at least 6 months immediately prior to enrol-
ment, confirmed by endoscopy and graded using the LA
grading system7.
Exclusion criteria included: other significant upper
gastrointestinal disorders (including Zollinger-Ellison
syndrome, gastric or duodenal ulcer, oesophageal stric-
ture, history of dysplasia in Barrett's oesophagus); intake
of medication liable to affect the outcome of the study
(including non-steroidal anti-inflammatory drugs); preg-
nancy, childbearing potential (unless taking suitable pre-
cautions) or lactation; alcohol and/or drug abuse; PPI use
within 4 weeks prior to the first endoscopy.
At visit 1 (baseline) physical examination was carried
out and the investigator assessed GERD symptoms. These
symptoms were on a fourpoint severity scale: none, mild,
moderate or severe. The number of days with symptoms
of heartburn over the previous 7 days was also recorded.
Patients were then randomized to receive esomeprazole
40 mg or pantoprazole 40 mg once daily for up to 8
weeks. Treatment compliance was determined by count-
ing unused capsules at the end of the study. Patients tak-
ing 75–110% of prescribed doses were deemed to have
been compliant with the dosing protocol.
At 4 weeks, patients underwent a further endoscopy
and their GERD symptoms were assessed in the same
way as at visit 1. Patients with unhealed EE and/or with
moderate or severe heartburn or acid regurgitation in
the prior 7 days, as assessed by investigators, continued
treatment for a further 4 weeks, after which EE and
GERD symptoms were re-assessed. From baseline to the
4-week visit, patients were instructed to record the se-
verity of heartburn on daily diary cards. Heartburn was
assessed using a four-graded scale: none, mild, moderate
or severe. Adverse events were recorded on each control
visit.
Statistical analyses
The study was planned to include 180 patients calcu-
lated by assuming 8 week healing rates of 96% and 92%
for esomeprazole and pantoprazole, respectively, using a
two-sides chi-squared test with 5% significance level and
a power of 95%. The assumptions about healing rates for
esomeprazole and pantoprazole were based on data from
previous studies8–12. Time to sustained resolution of
heartburn symptoms (defined as a period of seven con-
secutive days without heartburn) based on patient daily
diary cards, with differences analysed by log-rank test
and the difference between treatment groups for the pro-
portion of heartburn-free days analysed by analysis of
variance (ANOVA).
No formal statistical analysis was planned on adverse
event reports.
Results
In total, 180 patients were randomised to treatment
with either esomeprazole 40 mg or pantoprazole 40 mg. 2
patients were excluded from the intent-to-treat (ITT)
population because of intake of an unknown study drug,
and a further 2 patients because of study protocol viola-
tions. The baseline demographic and clinical characteris-
tics of the ITT population are shown in Table 1. There
were no clinically relevant differences between the two
treatment groups. Overall treatment compliance rates
were similar for the two treatment groups (esomeprazole
40 mg: 87.6%, pantoprazole 40 mg: 88.2%).
Esomeprazole 40 mg provided significantly greater
healing than pantoprazole 40 mg after 4 weeks of treat-
ment in patients with all grades of EE severity at base-
line (Table 2).
Esomeprazole-treated patients were healed after up
to 8 weeks of treatment similar those treated with panto-
prazole. Healing rates at 8 weeks, by LA grade at base-
line, are provided in Table 3.
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TABLE 1
BASELINE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
OF THE INTENT-TO-TREAT POPULATION (180 PATIENTS TO
TREATMENT WITH EITHER ESOMEPRAZOLE 40 mg OR
PANTOPRAZOLE 40 mg)
Characteristics
Esomeprazole 40 mg
(N=90)
n (%)
Pantoprazole 40 mg
(N=130)
n (%)
Gender – male 57 (63.3%) 59 (65.6%)
Age (years)
< 65 77 (85.6%) 79 (87.8%)
X (SD) 51.2 (14.5) 49.4 (13.9)
LA grade oesophagitis
A 37 (41.1%) 35 (38.9%)
B 40 (44.4%) 39 (43.3%)
C 13 (14.4%) 16 (17.8%)
Barrett s oesophagus,
Absent 84 (93.3%) 85 (94.4%)
Present 6 (6.7%) 5 (5.6%)
Helicobacter pylori status
negative 68 (75.6%) 70 (77.8%)
positive 22 (24.4%) 20 (22.2%)
TABLE 2
HEALING RATES OF EROSIVE OESOPHAGITIS (EE) AFTER
4 WEEKS TREATMENT WITH EITHER ESOMEPRAZOLE 40 mg
OR PANTOPRAZOLE 40 mg BY BASELINE LOS ANGELES (LA)
GRADE SEVERITY (INTENT-TO-TREAT POPULATION). 2 TEST
(ESOMEPRAZOLE VS. PANTOPRAZOLE)
LA grade
Esomeprazole 40 mg
n (%)
Pantoprazole 40 mg
n (%)
A 31 (83.8%) 29 (82.8%)
B* 31 (77.5%) 28 (71.8%)
C** 8 (61.5%) 8 (50.0%)
All patients* 70 (77.8%) 65 (72.2%)
*p<0.05, **p<0.01
The proportion of heartburn-free days was similar in
patients treated with esomeprazole 40 mg and to those
treated with pantoprazole 40 mg (mean values – esome-
prazole: 70.2%; pantoprazole: 69.8%). Time to sustained
heartburn resolution (the first of seven consecutive days
with no heartburn) was equally short for patients treated
with esomeprazole 40 mg and with pantoprazole 40 mg
(median days – 6).
Safety
A total of 12% patients in the esomeprazole group and
11% in the pantoprazole group had adverse events. The
most commonly reported of these were, in esomeprazole
group, nausea, dizziness and headache. In the panto-
prazole group, headache, diarrhoea and nausea.
All these adverse events were considered mild or mod-
erate in intensity and none were considered treatment-
-related.
Discussion
Comparative studies with PPIs are relatively few, but
some have shown advantages, albeit small, for esome-
prazole and pantoprazole. In a study comparing esome-
prazole (20 mg and 40 mg daily) with omeprazole (20 mg
daily), both esomeprazole doses proved significantly su-
perior to omeprazole in terms of oesophagitis healing af-
ter 8 weeks13. In terms of daytime symptom resolution,
esomeprazole 40 mg was superior to both esomeprazole
20 mg and omeprazole 20 mg. However, in terms of
night-time heartburn symptom relief both doses of eso-
meprazole were significantly better than omeprazole.
Compared with lansoprazole (30 mg daily), esomeprazole
(40 mg daily) proved superior in terms of both healing of
oesophagitis and night-time symptom resolution14.
In another comparative study, pantoprazole (40 mg
daily) was compared with omeprazole (40 mg daily) in
terms of healing of oesophagitis and symptom relief. No
significant differences were noted between the two treat-
ment groups. No distinction was made between daytime
and night-time heartburn15. Pantoprazole (40 mg daily)
was compared with lansoprazole (30 mg daily) and ome-
prazole (20 mg daily) in the resolution of heartburn
symptoms. Both omeprazole and pantoprazole were su-
perior to lansoprazole in the relief of heartburn symp-
toms16. Using continuous intra-gastric pH-metry, it was
demonstrated that equal doses of pantoprazole and ome-
prazole have similar potency to inhibit gastric acid se-
cretion17,18.
In a study pantoprazole (40 mg daily) and esomepra-
zole (40 mg daily) have an equivalent effect on intra-oe-
sophageal pH after repeated intake. Both drugs were safe
well tolerated19. Gillessen et al.20 and Scholten et al.21
have reported similar effectiveness for esomeprazole 40
mg and pantoprazole 40 mg, or even greater effective-
ness for latter drug in terms of speed of symptom resolu-
tion. In these studies however »GERD-related symp-
toms» included gastric complaints, feeling of satiety and
flatulence. As these symptoms are not generally accepted
as specifically related to GERD, and the studies lacked
statistical power to detect differences between treat-
ments, the studies added little information of the two
treatments in resolving classical GERD symptoms.
Crossover studies in healthy subjects and patients
with symptoms of GERD have shown that esomeprazole
is more effective than all other PPI for providing greater
time with pH>422,23. The results of large comparative
study demonstrate a therapeutic advantage of esomepra-
zole 40 mg over pantoprazole 40 mg for healing of EE
and providing resolution of associated heartburn12. This
result may be predicted, as healing of EE is inversely re-
lated to gastric acidity24, and esomeprazole has been
shown to provide greater suppression of gastric acidity
than standard doses of all other PPIs22.
The results of this study demonstrate a therapeutic
advantage of esomeprazole 40 mg over pantoprazole 40
mg for providing healing of EE after 4 weeks, but not af-
ter 8 weeks.
The proportion of heartburn-free days was similar in
patients treated with esomeprazole 40 mg and to those
treated with pantoprazole 40 mg (mean values – esome-
prazole: 70.2%; pantoprazole: 69.8%). Time to sustained
heartburn resolution (the first of seven consecutive days
with no heartburn) was equally short for patients treated
with esomeprazole 40 mg and with pantoprazole 40 mg
(median days – 6).
Treatment with esomeprazole and pantoprazole was
well tolerated. Similar rates of adverse events occurred
in both treatment groups.
In conclusion, the present study demonstrated that
esomeprazole 40 mg provides more effective healing of
EE than pantoprazole 40 mg after 4 weeks of treatment.
But, after 8 weeks of treatment esomeprazole and panto-
prazole 40 mg daily are equally effective in the treatment
of GERD.
Similar rates of adverse events occurred in both treat-
ment groups. Both study drugs were well tolerated, safe
and had high patient compliance.
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TABLE 3
HEALING RATES FOLLOWING UP TO 8 WEEKS TREATMENT
WITH ESOMEPRAZOLE 40 mg (N=130) OR PANTOPRAZOLE
40 mg (N=130) BY BASELINE LOS ANGELES (LA) GRADE OF
EROSIVE OESOPHAGITIS (EE) SEVERITY. 2 TEST (ESOME-
PRAZOLE VS. PANTOPRAZOLE)
LA grade
Esomeprazole 40 mg
n (%)
Pantoprazole 40 mg
n (%)
A 35 (94.6%) 33 (94.3%)
B 38 (95.0%) 37 (94.9%)
C 10 (76.9%) 12 (75.0%)
All patients 83 (92.2%) 82 (91.1%)
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ESOMEPRAZOL NASUPROT PANTOPRAZOLU U CIJELJENJU EROZIVNOG EZOFAGITISA
S A @ E T A K
Cilj ovog rada je bio komparirati u~inkovitost esomeprazola i pantoprazola u cijeljenju erozivnog ezofagitisa (EE) i
nestanku simptoma gastroezofagealne refluksne bolesti (GERB). U ovu multicentri~nu, randomiziranu, jednostruko
slijepu studiju je bilo uklju~eno 180 bolesnika s endoskopski dijagnosticiranim GERB-om i dobivali su esomeprazol 40
mg/dan (90 bolesnika) ili pantoprazol 40 mg/dan (90 bolesnika). Nakon 4. i 8. tjedna terapije kontrolirani su radi dokaza
cijeljenja EE i nestanka simptoma GERB-a. Esomeprazol bio je statisti~ki zna~ajno u~inkovitiji od pantoprazola u cije-
ljenju EE nakon 4 tjedna lije~enja (77.8% nasuprot 72.2%). Nakon 8 tjedana lije~enja u~inkovitost im je bila podjednaka
(92.2% nasuprot 91.1%). Postotak bolesnika bez simptoma GERB-a je bio podjednak nakon 4. i 8. tjedna lije~enja u obje
skupine.
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